Rochelle Fuhrmann has served as a member of our Board and Chair of the Audit Committee since March 2021 and a member of our Nominating and Corporate Governance Committee since July 2022. Ms. Fuhrmann currently serves as Chief Financial Officer of Maternal Newborn Health Innovations, PBC (MNHI) a public benefit corporation mobilized to address maternal and newborn health needs through innovation. Prior to joining MNHI in October 2022, Ms. Fuhrmann was the Vice President Audit and Enterprise Risk Management at Becton Dickinson (“BD”). In this role, she led an international team of audit professionals in the review of processes and controls. She also had accountability for the enterprise risk management program including the integration of risk concepts into strategic planning and working with stakeholders on risk identification and mitigation activities. In 2016, Ms. Fuhrmann helped establish the BD Foundation and served as Treasurer and as a member of its Board of Trustees. She joined BD in July 2015 as Senior Vice President and Chief Financial Officer, Life Sciences. Prior to joining BD, Rochelle held various positions responsible for the management of financial functions including accounting and financial reporting, investor relations, corporate finance, risk management and treasury, primarily in the pharmaceutical industry with companies such as Amneal Pharmaceuticals and Warner Chilcott plc. She previously served as a member of the board of directors of Concordia International Corp. and held the position of Audit Committee Chair for three years. Ms. Fuhrmann’s career started at Coopers & Lybrand LLC (now PricewaterhouseCoopers LLP) in Boston, MA. She is a certified public accountant (inactive) and holds a B.Sc. degree in accounting from the University of Rhode Island.

Source: Histogen Inc. on 03/13/2023